The reality of GLP-1s: Effective but unsustainable From an efficacy standpoint, there is no denying that GLP-1 medications work. Those who can afford, tolerate, and sustain GLP-1 use do lose weight
We used Cox regression models, adjusted for potential confounders, to estimate hazard ratios from day 366 after treatment initiation to account for cancer latency
But very few have the nerve to: Launch an ugly, bare-bones MVP
Avoid Desvenlafaxine (Pristiq), Duloxetine (Cymbalta), and Venlafaxine (Effexor) which fall into this SNRI category as they increase norepinephrine in the synapse and can increase sympathetic drive, already a problem for many POTS patients
A lot of the time, what feels like a plateau is actually part of the normal pattern of weight loss, not a sign that the medication has stopped working